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Background. Skin and soft tissue infections (SSTIs) in cancer patients represent a diagnostic challenge, as etiologic diagnosis is
often missing, and clinical assessment of severity is diﬃcult. Few studies have described (SSTIs) in patients with solid tumours
(STs). Patients and Methods. Records of patients with ST and SSTI, cared for at the University Hospital of Heraklion, from 2002 to
2006 were retrospectively studied. Results. A total of 81 episodes of SSTIs, occurring in 71 patients with ST, have been evaluated.
Their median age was 65 years (34–82). The most common underlying malignancy was breast cancer in 17 patients (24%). Most
episodes(89%)occurredinnonneutropenics.Cellulitis/erysipelaswasthemostcommonclinicalpresentation(56;69%).Bacterial
cultures were possible in 29 (36%) patients. All patients received antimicrobial therapy, while in 17 episodes (21%) an incision
and drainage was required. Treatment failure occurred in 20 episodes (25%). Five patients (7%) died due to sepsis. None was
neutropenic. Severe sepsis on admission (P = 0.002) and prior blood transfusion (P = 0.043) were independent predictors of
treatment failure. Conclusion. SSTIs can be life threatening among patients with ST. Early diagnosis and appropriate treatment are
of the utmost importance, since sepsis was proven a signiﬁcant factor of unfavourable outcome.
1.Introduction
Despite the advances in prevention and management of in-
fectious complications in cancer patients, they still remain
an important cause of morbidity and mortality [1–4]. Addi-
tionally, infections, especially in neutropenic patients, may
lead to delay in delivering planned chemotherapy, and this
event may have an impact upon patients’ survival [4–7].
Cancerpatientsareproneandhighlysusceptibletoinfec-
tions through obstructive processes or immune system dis-
orders due to the disease per se or cytotoxic therapy and/or
disruption of the integrity of anatomic barriers due to chem-
otherapy, radiotherapy, or intravascular devices [4, 8, 9].
Additionally, cancer patients are at risk of acquiring no-
socomial infections, since they often undergo invasive diag-
nostic and therapeutic procedures, intravenous line place-
ment, and hospitalization leading to the alteration of their
skin and gut microbial ﬂora [4, 10].
SSTIs in cancer patients represent a diagnostic challenge,
asetiologicdiagnosisisoftenmissing,andclinicalassessment
of severity is diﬃcult. Even small and innocuous in appear-
ance, lesions should be carefully evaluated, because due to
diﬀerent degree of immunosuppression, the inﬂammatory
response may be attenuated, and an apparently mild infec-
tion can become rapidly life threatening. Finally, SSTIs may
be the result of a systemic disease spreading to the skin
[4, 5, 11].
Therefore, early recognition and prompt administration
of appropriate empirical antimicrobial treatment are crucial,
especially in the neutropenic host [4, 5].
Few studies, however, have described SSTIs in immuno-
compromised patients, including those with cancer and neu-
tropenia [7–12].
The purpose of our study was to describe the clinical and
microbiological characteristics of SSTIs in patients with STs
and to determine factors leading to treatment failure.2 The Scientiﬁc World Journal
2.MaterialsandMethods
2.1.Setting. RecordsofpatientswithSTsandSSTIs,caredfor
at the University Hospital of Heraklion, from 2002 to 2006
were retrospectively studied.
2.2. Ethical Approval. The study has been approved by the
relevant committee of the University Hospital of Heraklion.
2.3. Study Design and Deﬁnitions. A SSTI was deﬁned as
community acquired if the episode developed in an outpa-
tient setting or within 48h after hospital admission in pa-
tients who did not ﬁt the criteria for a healthcare-associ-
ated SSTI. Healthcare-associated SSTI was deﬁned as the
episode developing at the time of hospital admission or
within 48h after admission if the patient had been hos-
pitalized or had been cared for at the day clinic of a hospital
during the preceding 30 days [13]. Hospital-acquired SSTI
was deﬁned as the episode developing after the ﬁrst 48 hours
of hospital stay [13].
SSTIsweregroupedascellulitisorerysipelas,furunclesor
carbuncles,cutaneousabscesses,centralvenouscatheterexit-
site infection, wound infections, pyomyositis, and herpes
zoster. Diagnoses were deﬁned using established criteria [5].
Sepsis, severe sepsis, and septic shock were also deﬁned
using established criteria [14]. In more details, sepsis was
deﬁned as the clinical syndrome that results from a dysreg-
ulated inﬂammatory response to an infection. It exists if two
or more of the following abnormalities are present, along
with either a culture-proven or visually identiﬁed infection:
temperature >38.5◦Co r<35◦C, heart rate >90 beats/min,
respiratory rate >20 breaths/min or PaCO2 < 32mmHg,
WBC > 12,000cells/mm3, <4000cells/mm3,o r>10 percent
immature (band) forms.
Severe sepsis was deﬁned as sepsis plus at least one of the
following signs of hypoperfusion or organ dysfunction: areas
of mottled skin, capillary reﬁlling requiring three seconds
or longer, urine output <0.5mL/kg for at least one hour, or
renalreplacementtherapy,lactate>2mmol/L,abruptchange
in mental status, abnormal electroencephalographic (EEG)
ﬁndings, platelet count <100,000platelets/mL, disseminated
intravascular coagulation, acute lung injury or acute respira-
tory distress syndrome (ARDS),cardiac dysfunction (i.e.,left
ventricular systolic dysfunction), as deﬁned by echocardiog-
raphy or direct measurement of the cardiac index [14].
Patient’s tumour response status to antitumour treat-
ment at the date of onset of the SSTI episode was classiﬁed as
completeresponse(CR),partialresponse(PR),stabledisease
(SD), or progressive disease (PD).
The deﬁnition of neutropenia was in accordance with the
NCI common toxicity criteria, version 2.0 [15].
Empirical antimicrobial treatment was considered ap-
propriate if the organism isolated from the infected area was
susceptible at least to one of the antimicrobials prescribed. In
any other case, treatment was considered inappropriate, on
the condition that the SSTI had been attributed to a known
organism.
Treatment failure was deﬁned by documented worsening
ofclinicalsignsandsymptomsoftheinfection,suchasrecur-
rence or worsening of fever, increased purulence, erythema,
induration, and/or tenderness at least 2 days after treatment
initiation, and if one of the following had happened: per-
formance of a second, not previously planned, incision and
drainage procedure, and/or readmission to the hospital due
to the same SSTI episode and/or death due to septic shock.
2.4. Data Review. Patient’s age, sex, underlying ST, blood
transfusions, antimicrobial treatment, medications, expo-
sure to radiotherapy or chemotherapy (during the preceding
30 days), and status of neoplastic disease (CR, PR, SD,
PD), performance status (PS) and any invasive procedure
performed (during the preceding 10 days), date of onset
of the episode, date of previous admission, results of com-
plete blood count (CBC) (total white blood cell count and
diﬀerential, hemoglobin level, and platelets), presence of
fever, hypotension, tachycardia, tachypnea, shock, signs of
localized infection as well as antimicrobial treatment admin-
istered for every episode were systematically recorded.
Microbiological information included the results of all
relevantcultures,thesourceandtypeofisolatedpathogen(s),
and its (their) susceptibility pattern(s).
2.5.StatisticalAnalysis. Bivariate analyses were conducted by
Pearson’s chi-square test and Fisher’s exact test, to compare
categorical variables. For continuous variables, t-test and
nonparametric Mann-Whitney test (for not normally dis-
tributed variables) were used. Variables with a P-value < 0.5
were subsequently included in a stepwise logistic regression
multivariate analysis, in order to determine independent risk
factorsfortreatmentfailure.TheSPSSforWindowssoftware,
version 16.0 (SPSS Inc., Chicago, IL, USA), was used for all
statistical analyses.
3. Results
3.1. Patient Characteristics. Eighty-one episodes of SSTIs oc-
curring in 71 patients were identiﬁed. The median age of
patients was 65 (range 34–82) years. There were 38 males
(53.5%). The most common underlying malignancy was
breast cancer in 17 patients (24%), followed by colon in 14
(20%) lung in 13 (18%), genital in 10 (14%), head and neck
i n5( 7 % ) ,u r i n a r yt r a c ti n4( 6 % ) ,a n ds a r c o m ai n3( 4 % )
(Table 1).
At the onset of the SSTI 3 patients had a CR (5%), 2 had
a PR (2.5%), 29 had SD (38%), and 47 had PD (58%). At the
time of the episode, 24 patients (34%) had a PS: 0, 41 ( 58%)
PS:1, 12 (17%) PS: 2, and 4 (5.5%) PS 3.
Fiftyoutof81SSTIepisodes(62%)werehealthcare-asso-
ciated, 25 (35%) community, and 6 (7%) hospital acquired.
A central venous catheter was present in 15 episodes
(18.5%), blood had been transfused during the preceding
10 days in 21 (26%), and invasive procedure was recorded
in 30 (37%). Chemotherapy and radiotherapy during the
preceding 30 days had been administered in 52 (64%) and 19
(23.5%) episodes, respectively, and antimicrobial treatment
in 30 (37%).
Neutropenia was present only in 9 episodes (11%), being
grade IV in 4, with median duration of 4 days (3–21).The Scientiﬁc World Journal 3
Table 1: Patients’ characteristics.
Characteristics No of patients (%)
Sex of patients
Male 38 (53.5%)
Female 33 (46.5%)
Median age of patients [range] 65 [34–82]
Underlying malignancy
Breast 17 (24%)
Colorectal 14 (20%)
Lung 13 (18%)
Genital 10 (14%)
Head & neck 5 (7%)
Urinary tract 4 (6%)
Sarcoma 3 (4%)
Hepatobiliary 2 (3%)
Pancreas 1 (1.3%)
Stomach 1 (1.3%)
Unknown primary 1 (1.3%)
Table 2: Risk factors of the SSTIs episodes.
Factor Episodes (%)
Recent chemotherapy 52 (64)
Prior invasive procedure 30 (37)
Previous antimicrobial therapy 30 (37)
Prior blood transfusion 21 (26)
Recent radiotherapy 19 (23.5)
Central venous catheter 15 (18.5)
Neutropenia 9 (11)
Factorspotentiallyassociatedwiththeinfectiousepisodesare
summarized in Table 2.
3.2. Clinical Presentation. Cellulites/erysipelas were the most
common presentations (44 episodes; 54%), followed by ab-
scesses (18; 22%) and exit-site infections (8; 10%). Regard-
ing the site of infection, SSTIs were more frequently located
on the trunk (28; 35%) followed by the genital and/or
perirectal region (19; 23%).
Considering signs and symptoms, erythema was present
in59episodes(70%),swellingin41(51%)andlocalizedpain
in 34 (42%). At the time of admission, fever was present in
52 (64%) with median duration 3.5 days (1–14).
All the surgical site infections were wound infections
while in all catheter-related infections, catheters had been
removed.
Sepsis was present on admission in 43 episodes (53%)
and severe sepsis in 15 (18.5%), while among the latter
episodes 5 (4%) were complicated by septic shock. Clinical
characteristics of the episodes are summarized in Table 3.
3.3. Microbiology. Pathogens were isolated from skin and/or
soft tissue lesions in 29 episodes (36%). One pathogen
was isolated from each of the 23 episodes, while two from
Table 3: Clinical characteristics of SSTI episodes.
Characteristic No of episodes (%)
Type of SSTI
Cellulitis/erysipelas 44 (54)
Abscess 18 (22)
Exit-site infection 8 (10)
Wound infection 5 (6)
Herpes zoster 4 (5)
Furuncles/carbuncles 1 (1)
Pyomyositis 1 (1)
Site of infection
Head and neck 10 (12)
Trunk 28 (35)
Upper extremities 11 (14)
Lower extremities 13 (16)
Genitoperineal/perirectal 19 (23)
Signs and symptoms
Erythema 59 (70)
Fever 52 (64)
Swelling 41 (51)
Localized pain 34 (42)
Sepsis 43 (53)
Severe sepsis 15 (18.5)
Septic shock 3 (4)
Table 4: Microorganisms isolated from 29 SSTIs episodes.
Pathogens Total no of isolates
Gram negative
Pseudomonas aeruginosa 7
Escherichia coli 7
Klebsiella pneumoniae 2
Enterobacter cloacae 2
Citrobacter freundii 1
Gram positive
Enterococcus faecalis 6
Staphylococcus epidermidis 5
Staphylococcus aureus 3
Enterococcus faecium 1
Anaerobes
Bacteroides fragilis 1
Total 35
the remaining 6. Gram-negative bacteria were isolated in
13 (45%), with Escherichia coli (6 out of 13; 46%) and
Pseudomonas aeruginosa (4; 31%) being the most frequent,
followed by Enterobacter cloacae (2; 15%) and Klebsiella
pneumoniae (1; 8%). Gram-positive organisms were isolated
in 9 episodes (11%) with Staphylococcus epidermidis being
the most common (4 out of 9; 45%) followedby Enterococcus
faecalis (3; 33%) and Staphylococcus aureus (2; 22%). The
isolated pathogens isolated are shown in Table 4.
Blood cultures were performed in all patients upon
admission. No pathogens were isolated from blood.4 The Scientiﬁc World Journal
Table 5: Characteristics of 5 patients with fatal outcome.
Age Sex Underlying malignancy Type of infection Isolated organisms Absolute neutrophils count Initial inappropriate therapy
76 F Colorectal Cellulitis Escherichia coli 15000 Yes
64 M Lung Abscess polymicrobial 18100 Yes
82 F Breast Abscess negative 4700 —
48 M Lung Cellulitis Escherichia coli 10100 Yes
56 M Colorectal Abscess Escherichia coli 29500 Yes
3.4. Therapy. All patients received antimicrobial therapy,
while in 17 episodes (21%) an incision and drainage were
required.
Initial antimicrobial treatment was considered inappro-
priate in 3 out of 20 episodes (15%) treated successfully and
in 7 out of 9 (78%) treated unsuccessfully (P = 0.001).
3.5. Outcome and Predictors of Failure. Treatment failure
occurred in 20 episodes (25%). An additional drainage pro-
cedure was necessary in 8. Seven episodes recurred with
subsequenthospital admissionandimprovedaftertreatment
with second-line antimicrobial regimens. Five patients had
a fatal outcome due to septic shock. Four of them have
been inappropriately treated, and none was neutropenic.
The overall mortality reached 7%. Characteristics of the 5
patients who died are shown in Table 5.
In univariate analysis, three factors were found to have
statistically signiﬁcant association with treatment failure:
prior blood transfusion, presence of severe sepsis on admis-
sion, and hospital-acquired or health-care associated infec-
tion.
Multivariate logistic regression analysis indicated that
presence of severe sepsis on admission (OR 21.921, 95% CI:
2.970–161.815; P = 0.002) and prior blood transfusion (OR
4.460, 95% CI: 1.049–18.954; P = 0.043) were independent
predictors of treatment failure.
4. Discussion
The present study showed that SSTIs can be life threatening
in patients with ST even in the absence of neutropenia. The
majority of SSTIs were health-care associated, with gram-
negative bacteria being most commonly isolated.
Cancer patients are at increased risk of infections,
including SSTIs, due to multiple factors such as immuno-
suppression resulting from chemotherapy or due to the
malignancy itself, impairment of normal leukocyte function,
disruption ofanatomicalbarriers,orobstructivephenomena
[2–5, 7, 16].
SSTIs in patients with STs may have diﬀerent etiology
than those occurring in the general population and var-
iable clinical presentations due to diﬀerent degrees of immu-
nosuppression and type of neoplasia. Additionally, a broad
range of diﬀerential diagnoses that may mimic skin infec-
tions should be taken in consideration such as drug and
transfusion-associatedrashes,hemorrhagicareas,andmalig-
nancies.
In patients with tumours, a normally mild SSTI can be
rapidly transformed into a life-threatening disease or can be
a manifestation of a serious systemic disease spreading to the
skin[4,5].Furthermore,SSTIs,especiallyinneutropenicpa-
tients, may delay the delivery of planned chemotherapy with
impact on the outcome of the underlying malignancy [6].
Although infectious complications in patients with STs
have been well described, speciﬁc data on SSTIs are rare and
inconclusive [4, 5, 7–12].
The present results indicate that SSTIs can be life-threat-
ening among patients with STs, even in the absence of neu-
tropenia. Neutropenia remains an important risk factor for
infection in patients with cancer although in the present
study only a limited number of patients were neutropenic
[2, 16, 17].
Additionally cancer patients are at increased risk of no-
socomial infections since they often undergo invasive pro-
cedures, intravenous line placement, and hospitalizations
leading to the alteration of their microbial ﬂora [17]. Indeed
the present study revealed that 62% of the episodes were
health care associated while an additional 7% was pure
nosocomial. This is not surprising considering the fact that
most cancer patients nowadays, including the present ones,
receive routine care in day clinics as outpatients [16, 17].
In the present study, cellulitis and erysipelas were the
most common clinical presentations. Microorganisms were
isolated from lesions in 36% of the episodes with gram-
negativepathogensbeingthemostcommonbacteriaisolated
and this is in contrast with other studies in the general
population in which gram-positive organisms, Staphylococ-
cus aureus and Streptococcus pyogenes, are the predominant
pathogens[18,19].Thereare,however,studiesinaccordance
with our results indicating that gram-negative bacteria play
an important role as causative agents of skin and soft-tissue
infections in many areas of the world, especially in patients
with liver cirrhosis, malignancy, and alcoholism [20, 21].
It is worth noting that none of the 71 patients had
positive blood cultures. Two recent literature reviews con-
cludedthatbloodculturesarenotnecessaryinacutecellulitis
in immunocompetent hosts [22, 23]. Although the present
results are negative, the question whether blood cultures are
helpful in immunocompromised patients with SSTIs has not
yet been answered [5].
The role of antimicrobial treatment of SSTIs is also not
fullyclariﬁed.Therearereportsdescribingcuresofimmuno-
competent patients receiving inappropriate or no treatment
at all [24]. Furthermore, literature does not elucidate if
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withSSTIsplaysacruciallynegativerole,consideringalsothe
fact that may delay the antitumour therapy due to prolonged
infection [6]. However, in the present study, inappropriate
initial antibiotic therapy was signiﬁcantly associated with
treatment failure. Additionally, four out of ﬁve patients with
fatal outcome had received inappropriate treatment.
Initial empirical antibiotic selection should be based on
severity stratiﬁcation of SSTIs and clinical care guidelines
[5]. In stable pts with skin/soft tissue infections empiric
therapy is usually aimed against gram-positive pathogens.
However, as health-care-associated infections occur often
among patients with solid tumors, empirical treatment with
antimicrobial agents covering gram-negative bacteria should
also be considered.
Factors such as recent chemotherapy, prior invasive
procedures, previous antimicrobial treatment, and prior
blood transfusion are commonly associated with SSTIs in
patients with STs [4, 5].
Multivariate analysis revealed that only two clinical fac-
tors had a statistically signiﬁcant association with treatment
failure: the occurrence of severe sepsis and the prior blood
transfusion.
Severe sepsis is an already known important complica-
tion in cancer patients developing infections that carries a
high mortality rate [25]. The rate of sepsis occurring in the
present patients was high. No other source except the SSTIs
could be implicated for the septic episodes. This ﬁnding
indicates the high risk of this type of infections in the present
patients’ population.
The clinical signiﬁcance of immune suppression sec-
ondary to blood transfusion in cancer patients remains
controversial. Adverse eﬀects of blood transfusions have
been documented in patients undergoing colorectal and
gastrointestinal surgery as demonstrated by higher infection
rates among them [26, 27]. On the contrary, a meta-analysis
that examined perioperative allogenic blood transfusion in
surgical oncology patients concluded that there was no
evidence to support adverse infectious sequelae [28].
SSTIs are usually curable [5]. However, in the present
study, mortality reached 7%. A great number of the present
population presented with severe and life-threatening infec-
tions. This can be explained by the fact that many infectious
episodes were healthcare associated or nosocomial.
Although 5 patients died due to septic shock that was
related to some degree to their infection, no organisms were
isolated from blood. It is of note that the disease’s status and
bad performance status did not aﬀect signiﬁcantly outcome.
This is probablydue to the fact that a relatively small number
of patients had a PS ≥2.
In conclusion, the majority of SSTIs in cancer patients
of the present study were healthcare associated, with gram-
negative bacteria being most commonly isolated from the
infected sites. Furthermore, the study showed that SSTIs can
be life threatening in this patients’ population, even in the
absence of neutropenia. Early diagnosis is of utmost impor-
tance,sincesepsisonadmissionhasbeenprovenasigniﬁcant
factorofunfavourableoutcome.Although7%ofthepatients
died due to septic shock that was related to some degree to
their infections, no organisms were isolated from blood.
Acknowledgment
This research was presented in part at 19th European Con-
gress of Clinical Microbiology and Infectious Diseases,
Helsinki, Finland, 16–19 May l, 2009.
References
[1] T.J.Smith,J.Khatcheressian,G.H.Lymanetal.,“2006Update
of recommendations for the use of white blood cell growth
factors: an evidence-based clinical practice guideline,” Journal
of Clinical Oncology, vol. 24, no. 19, pp. 3187–3205, 2006.
[2] A.G.Freifeld,E.J.Bow,K.A.Sepkowitzetal.,“Executivesum-
mary: clinical practice guideline for the use of antimicrobial
agents in neutropenic patients with cancer: 2010 update by
the infectious diseases society of America,” Clinical Infectious
Diseases, vol. 52, no. 4, pp. 427–431, 2011.
[3] E. Robenshtok, A. Gafter-Gvili, E. Goldberg et al., “Anti-
fungal prophylaxis in cancer patients after chemotherapy or
hematopoietic stem-cell transplantation: systematic review
and meta-analysis,” Journal of Clinical Oncology, vol. 25, no.
34, pp. 5471–5489, 2007.
[4] P. A. Pizzo, J. Meyers, A. G. Freifeld, and T. Walsh, “Infection
in the cancer patient,” in Cancer Principle and Practice of
Oncology, V. T. DeVita, S. Hellman, and S. Rosenberg, Eds.,
pp. 2292–2337, Lippincot Company, Philadelphia, Pa, USA,
8th edition, 2009.
[5] D. L. Stevens, A. L. Bisno, H. F. Chambers et al., “Practice
guidelines for the diagnosis and management of skin and soft-
tissue infections,” Clinical Infectious Diseases, vol. 41, no. 10,
pp. 1373–1406, 2005.
[6] S. Khan, A. Dhadda, D. Fyfe, and S. Sundar, “Impact of
neutropenia on delivering planned chemotherapy for solid
tumours: original article,” European Journal of Cancer Care,
vol. 17, no. 1, pp. 19–25, 2008.
[7] E. Toussaint, E. Bahel-Ball, M. Vekemans et al., “Causes of
feverincancerpatients(prospectivestudyover477episodes),”
Supportive Care in Cancer, vol. 14, no. 7, pp. 763–769, 2006.
[8] D. Yadegarynia, J. Tarrand, I. Raad, and K. Rolston, “Current
spectrum of bacterial infections in patients with cancer,”
ClinicalInfectiousDiseases,vol.37,no.8,pp.1144–1145, 2003.
[9] M. Kamana, C. Escalante, C. A. Mullen, S. Frisbee-Hume,
and K. V. I. Rolston, “Bacterial infections in low-risk, febrile
neutropenic patients: over a decade of experience at a
comprehensivecancercenter,”Cancer,vol.104,no.2,pp.422–
426, 2005.
[10] I. R. O. Novakova, J. P. Donnelly, and B. De Pauw, “Potential
sites of infection that develop in febrile neutropenic patients,”
Leukemia and Lymphoma, vol. 10, no. 6, pp. 461–467, 1993.
[11] F. A. Lopez and C. V. Sanders, “Dermatologic infections in
the immunocompromised(non-HIV) host,” Infectious Disease
Clinics of North America, vol. 15, no. 2, pp. 671–702, 2001.
[12] J. S. Wolfson, A. J. Sober, and R. H. Rubin, “Dermato-
logic manifestations of infections in immunocompromised
patients,” Medicine, vol. 64, no. 2, pp. 115–133, 1985.
[13] T. C. Horan, M. Andrus, and M. A. Dudeck, “CDC/NHSN
surveillance deﬁnition of health care-associated infection and
criteriaforspeciﬁctypesofinfectionsintheacutecaresetting,”
American Journal of Infection Control, vol. 36, no. 5, pp. 309–
332, 2008.
[14] MembersoftheAmericanCollegeofChestPhysicians,“Amer-
icanCollegeofChestPhysicians/SocietyofCriticalCareMed-
icine consensus conference: deﬁnitions for sepsis and organ6 The Scientiﬁc World Journal
failure and guidelines for the use of innovative therapies in
sepsis,” Critical Care Medicine, vol. 20, pp. 864–874, 1992.
[15] National Cancer Institute, “Common Toxicity Criteria (NCI-
CTC) v2.0,” http://ctep.cancer.gov/protocolDevelopment/ele-
ctronic applications/docs/ctcv20 4-30-992.pdf.
[16] S. Vento and F. Cainelli, “Infections in patients with cancer
undergoing chemotherapy: aetiology, prevention, and treat-
ment,” Lancet Oncology, vol. 4, no. 10, pp. 595–604, 2003.
[17] S.H.SuttonandJ.P.Flaherty,“Infectionsassociatedwithsolid
tumors,” Cancer treatment and research, vol. 96, pp. 105–141,
1998.
[18] E. W. Hook III, T. M. Hooton, and C. A. Horton, “Microbi-
ologic evaluation of cutaneous cellulitis in adults,” Archives of
Internal Medicine, vol. 146, no. 2, pp. 295–297, 1986.
[19] T. Duvanel, R. Auckenthaler, P. Rohner, M. Harms, and J.
H. Saurat, “Quantitative cultures of biopsy specimens from
cutaneouscellulitis,”ArchivesofInternalMedicine,vol.149,no.
2, pp. 293–296, 1989.
[20] G. J. Moet, R. N. Jones, D. J. Biedenbach, M. G. Stilwell, and
T. R. Fritsche, “Contemporary causes of skin and soft tissue
infections in North America, Latin America, and Europe: re-
port from the SENTRY Antimicrobial Surveillance Program
(1998–2004),” Diagnostic Microbiology and Infectious Disease,
vol. 57, no. 1, pp. 7–13, 2007.
[21] C. M. Chang, H. C. Lee, N. Y. Lee et al., “Community-
acquired Klebsiella pneumoniae complicated skin and soft-
tissue infections of extremities: emphasis on cirrhotic patients
andgasformation,”Infection,vol.36,no.4,pp.328–334,2008.
[22] A. M. Mills and E. H. Chen, “Are blood cultures necessary in
adults with cellulitis?” Annals of Emergency Medicine, vol. 45,
no. 5, pp. 548–549, 2005.
[23] A. Stevenson, P. Hider, and M. Than, “The utility of blood
cultures in the management of non-facial cellulitis appears to
be low,” New Zealand Medical Journal, vol. 118, no. 1211, pp.
1351–1357, 2005.
[ 2 4 ]K .Z .P a y d a r ,S .L .H a n s e n ,E .D .C h a r l e b o i s ,H .W .H a r r i s ,
and D. M. Young, “Inappropriate antibiotic use in soft tissue
infections,” Archives of Surgery, vol. 141, no. 9, pp. 850–854,
2006.
[25] M.D.Williams,L.A.Braun,L.M.Cooperetal.,“Hospitalized
cancer patients with severe sepsis: analysis of incidence, mor-
tality, and associated costs of care,” Critical Care, vol. 8, no. 5,
pp. R291–R298, 2004.
[26] M. Braga, A. Vignali, G. Radaelli, L. Gianotti, and V. Di Carlo,
“Association between perioperative blood transfusion and
postoperative infection in patients having elective operations
for gastrointestinal cancer,” European Journal of Surgery, vol.
158, no. 10, pp. 531–536, 1992.
[27] C. D. Morris, K. Sepkowitz, C. Fonshell et al., “Prospective
identiﬁcation of risk factors for wound infection after lower
extremity oncologic surgery,” Annals of Surgical Oncology, vol.
10, no. 7, pp. 778–782, 2003.
[28] F. A. McAlister, H. D. Clark, P. S. Wells, and A. Laupacis,
“Perioperative allogeneic blood transfusion does not cause
adverse sequelae in patients with cancer: a meta-analysis of
unconfounded studies,” British Journal of Surgery, vol. 85, no.
2, pp. 171–178, 1998.